{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:59:59Z","timestamp":1782889199499,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T00:00:00Z","timestamp":1453161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ahj.2016.01.005","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T03:16:39Z","timestamp":1453173399000},"page":"175-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana M.","family":"Al-Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Cecilia","family":"Bahit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"L\u00f3pez-Send\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Renda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3 Suppl","key":"10.1016\/j.ahj.2016.01.005_bb0005","doi-asserted-by":"crossref","first-page":"287S","DOI":"10.1378\/chest.126.3_suppl.287S","article-title":"Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Levine","year":"2004","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.ahj.2016.01.005_bb0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.ahj.2016.01.005_bb0015","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-147-8-200710160-00018","article-title":"Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation","volume":"147","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ahj.2016.01.005_bb0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.ahj.2016.01.005_bb0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.005_bb0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.ahj.2016.01.005_bb0035","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.ahj.2016.01.005_bb0040","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.01.005_bb0045","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.01.005_bb0050","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?","volume":"290","author":"Go","year":"2003","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ahj.2016.01.005_bb0055","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.005_bb0060","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.STR.0000208294.46968.a4","article-title":"Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation","volume":"37","author":"Birman-Deych","year":"2006","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.005_bb0065","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejim.2013.04.008","article-title":"Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study","volume":"24","author":"Gussoni","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"20","key":"10.1016\/j.ahj.2016.01.005_bb0070","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1136\/heartjnl-2014-305486","article-title":"Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe","volume":"100","author":"De Caterina","year":"2014","journal-title":"Heart"},{"issue":"15","key":"10.1016\/j.ahj.2016.01.005_bb0075","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.ahj.2016.01.005_bb0080","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes","volume":"63","author":"Hylek","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2016.01.005_bb0085","article-title":"Anemia predicts bleeding and mortality, but not stroke, in patients with AF: insights from the ARISTOTLE trial","volume":"130","author":"Westenbrink","year":"2014","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ahj.2016.01.005_bb0090","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","article-title":"Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)","volume":"63","author":"Goodman","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2016.01.005_bb0095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.ahj.2016.01.005_bb0100","first-page":"1715","article-title":"The causes of intracranial hemorrhagic complications induced by antivitamins K","volume":"87","author":"Lacroix","year":"1994","journal-title":"Arch Mal Coeur Vaiss"},{"issue":"8","key":"10.1016\/j.ahj.2016.01.005_bb0105","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"issue":"19","key":"10.1016\/j.ahj.2016.01.005_bb0110","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ahj.2016.01.005_bb0115","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.amjmed.2015.03.034","article-title":"Net clinical benefit of non-vitamin K antagonist oral anticoagulants versus warfarin in phase III atrial fibrillation trials","volume":"128","author":"Renda","year":"2015","journal-title":"Am J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316000168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316000168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:16Z","timestamp":1762077376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870316000168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":23,"alternative-id":["S0002870316000168"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2016.01.005","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2016.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2016.02.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}